SGLT2 inhibitor manufacturers must conduct another post-marketing study looking at ketoacidosis after FDA decided to add a warning to the class label.
SGLT2 Inhibitors' Warning On Ketoacidosis Recommends Drug Holidays
Sponsors must also conduct another post-marketing study.